Khosla Ventures and Hanabi Capital co-lead funding for autonomous AI platform that continuously builds, tests and improves digital experiences

SAN FRANCISCO, Nov. 9, 2026 — Coframe, the company building websites, landing pages, and ads that continuously generate, test and improve themselves, today announced it has raised $35 million in total funding, including a $25 million Series A co-led by Khosla Ventures and Hanabi Capital, with participation from leaders at OpenAI, Anthropic, and Google DeepMind.

Founder and CEO Josh Payne calls the company’s vision “the living internet.” Instead of every visitor seeing the same static website, Coframe plugs into a company’s website or advertising campaigns and continuously generates, tests and deploys new variations, personalizing what each visitor sees and improving performance in real time. Apps, email, and other digital experiences are next on the roadmap.

Behind it is a specialized transformer model trained on user interactions, and a team of AI agents: a strategist, a designer, a software engineer, a QA specialist, and a data scientist, that can ideate, build, test and optimize hundreds of website and ad variations in minutes.

Coframe has generated more than $300 million in incremental revenue for its customers, including conversion rate increases of 158% for Dropbox, 410% for Replit, and 60% for Cash App. And the results come fast: for one Fortune 500 customer, Coframe launched dozens of variations and delivered a 70% lift in conversion within 30 days of contract signature. Across its customer base, which includes Dropbox, BCG, Block, Backcountry, Sur La Table, and other leading brands, conversion rates have improved by more than 20% on average.

At Dropbox, an experiment that previously required four weeks of engineering, design, and QA work was built and deployed in 30 minutes with Coframe. Across thousands of variants, the platform has achieved a 39% experiment win rate, more than three times the industry average, while increasing customers’ testing velocity ten times or more.

“We’re building an internet that improves itself,” said Josh Payne, founder and CEO of Coframe. “A digital experience should understand what it is trying to accomplish, adapt to the person interacting with it and learn from every result. Instead of waiting months for the next redesign, companies should have websites and applications that get better every day.”

“For decades, the web has been frozen in place, showing every visitor essentially the same page,” said Vinod Khosla, founder of Khosla Ventures. “Coframe is building the living internet, where two people can visit the same website and have completely different experiences, personalized to who they are and what they need. These interfaces continuously learn and improve themselves. This is a huge leap beyond traditional A/B testing and the next iteration of the internet.”

“The way most companies build and manage their user interfaces today is wrong, and in a year or two it will be obvious why that is,” said Pavlo Razumovskyi, co-founder and VP of Engineering of Coframe. “User interfaces should improve themselves, and be personalized to every user.”

Coframe is also building for a future where a growing share of web traffic comes from AI agents that research, compare and buy on people’s behalf. That work is already underway through a collaboration with OpenAI on its ChatGPT ads offering, enabling customers to optimize the ad and the landing page as one continuously learning experience, building on an earlier partnership between the companies on training a specialized model for generating on-brand code and creative assets. Coframe is also baking agent best practices directly into every website it builds.

Payne founded Coframe in 2023 after studying Mathematics and Computer Science at Stanford University with a focus in AI, where he completed undergrad and dropped out of the MS and MBA programs. He previously co-founded Autograph with Tom Brady, which reached a valuation of more than $2 billion, and created GPT-Migrate, an early autonomous coding agent that became the top-ranked project on GitHub globally.

Coframe has acquired companies founded by two early Optimizely executives: Bo Mohazzabi, now VP of Go-to-Market, and Steven Ebin, now General Manager of Revenue Optimization.

About Coframe

Coframe is building the living internet: digital experiences that continuously generate, test, learn and improve themselves for humans and AI agents. Its autonomous AI agents combine strategy, design, software engineering and data analysis to optimize websites, landing pages and advertising. They are powered by Coframe’s proprietary foundation model of user behavior, a custom transformer trained on how people move through digital experiences across hundreds of millions of sessions each month, so every experiment makes the next one smarter. Founded in 2023 by AI researcher and entrepreneur Josh Payne, Coframe has generated more than $300 million in incremental revenue for its customers. The company is backed by Khosla Ventures, Hanabi Capital, Nat Friedman, Antler, and other leading technology investors. Learn more at coframe.com.

Media Contact

[email protected]

SOURCE Coframe Inc.

AI lab brings its AI tutor to families in all 50 states as every prior institutional investor returns for its newest funding round.

SAN FRANCISCO, Nov. 9, 2026 — Astral, an AI lab building hyper-personalized education, today announced it has raised a total of $5.5 million to bring its AI tutor to families in all 50 states. Thousands of families in more than 33 states already use it, and its students master entire grades five times faster than their public school peers per hour of learning time.

For most of history, great thinkers were shaped one-on-one. Leonardo da Vinci had Verrocchio. Michelangelo had Ghirlandaio. Galileo had Ricci. The Renaissance, one of the greatest bursts of art, science, and invention the world has ever seen, was built by hyper-personalized education.

Today, that kind of teaching is rationed to families who can afford private tutors or $40,000-a-year private schools. Astral believes AI can end the ration, and that teaching every child the way they learn best will unlock the Next Renaissance.

Every civilization lives or dies by its thinkers. Ours is at risk. Most children are still taught in rows, at one pace, from one mass-produced textbook, and only 28 percent of American eighth graders are proficient in math. Now AI can even do their homework for them. The next generation risks never learning to think at all.

Astral uses AI to do the opposite. Its tutor doesn’t think for children; it teaches them to think. It learns each child’s gaps, pace, and way of reasoning, then writes their lessons around them, replacing the mass-produced textbook with a curriculum built for one student. It costs $100 per month, a fraction of private-school tuition, and is approved for Education Savings Account (ESA) funding in nine states, with more to come.

“What excites me about Astral is not simply the sophistication of its AI, but the educational principles driving its design: a living curriculum that continuously adapts to each learner,” said Victor Pereira, Co-Chair of the Teaching and Teacher Leadership Program at the Harvard Graduate School of Education.

Cathy Duffy, homeschooling legend and founder of CathyDuffyReviews.com, who has reviewed homeschool curriculum for more than 30 years, said: “Nearly all of the curriculum I’ve reviewed is written for an average student who doesn’t exist. Astral is truly innovative. It builds the curriculum around the child instead of making the child fit the curriculum.”

“My daughter used to say she just wasn’t a math person. Turns out she just needed math taught her way. Now it’s her favorite subject,” said Cassie Lollett, a parent whose two children use Astral.

Results like these brought back every institutional investor from Astral’s pre-seed, most investing above their pro rata allocations. The latest round was led by Andre Charoo, GP at MapleVC, with continued funding from Stand Together Ventures Lab (STVL), Conversion Capital, and Original Capital, among many others.

“I’ve spent two decades working to get great curriculum to every kid. Astral takes the next step: curriculum built for each one,” said Scott McNealy, co-founder of Sun Microsystems, which Oracle acquired for $7.4 billion, and founder of the free-curriculum nonprofit Curriki.

“Every great mind in history had someone who taught them, and only them. Genius has never been rare. The education that unlocks it has been,” said Shivam Sharma, CEO of Astral.

“No child is unteachable,” said Fhad Sheikh, CPO of Astral. “This funding brings hyper-personalized learning to every family in America.”

The AI tutor is Astral’s first step. As an AI lab, Astral is building towards a larger purpose: a society of great thinkers. The last Renaissance brought a civilization back to life. Astral believes the next one will be built the same way: one child at a time, each taught the way they learn best.

About Astral
 Astral is an AI lab on a mission to build a society of great thinkers. It believes the next renaissance will be unlocked by hyper-personalized education: the one-on-one teaching that shaped history’s greatest minds, made available to every child. Its first product, an AI math tutor for grades K-8, builds every lesson around how each child thinks. Founded by Shivam Sharma and Fhad Sheikh, Astral is backed by MapleVC, Stand Together Ventures Lab, Conversion Capital, and Original Capital, among others. Learn more at astralhomeschool.com.

SOURCE Astral

Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation

SHANGHAI, Nov. 9, 2026 — Sanyou Biopharmaceuticals Co., Ltd. (“Sanyou Bio”) recently announced the completion of a Series C financing round worth nearly RMB 100 million. The round was exclusively funded by Zero2IPO Industry Investment, a fund managed by Zero2IPO Group.

This financing represents strong recognition from the capital markets of Sanyou Bio’s technological capabilities, innovative drug R&D system, and future growth potential. It also marks a new stage in the company’s development in innovative drug R&D and commercialization.

With the vision of becoming a front-runner in global innovative drug R&D, Sanyou Bio has built a world-leading AI-Super-Trillion Antibody Library (AI-STAL), an integrated wet-lab and dry-lab Sanyou AI-Drug Accelerator (SAI-DA), and Clicklinks, a collaborative innovation platform for original drug discovery and development. Driven by three interconnected pillars—innovation at the source, intelligent acceleration, and pipeline-driven development—the company is systematically addressing bottlenecks in early-stage drug discovery, connecting the entire preclinical R&D value chain, and joining forces with partners to build a new ecosystem for innovative drug development.

From technology platform development to innovation ecosystem building, and from enhancing R&D capabilities to advancing drug pipeline translation, Sanyou Bio is exploring new pathways to improve the efficiency of innovative drug R&D and enhance industrial value through a systematic, intelligent, and global development strategy. 

Previously, Sanyou Bio completed its Series A financing in May 2020, Series B financing in June 2021, and Series B+ financing in August 2022. The completion of this Series C financing marks another significant milestone in the company’s development, bringing its total funding raised to nearly RMB 300 million.

Synergy Across Three Core Platforms: Building an AI-Driven Innovative Drug R&D System

In recent years, the deep integration of artificial intelligence and life sciences has been reshaping the technological pathways and industrial landscape of innovative drug development. Advancing innovative drug R&D requires not only continuous breakthroughs in the efficiency of early-stage molecular discovery, but also the integration of critical links spanning drug design, experimental validation, R&D advancement, and commercialization.

In response to these industry needs, Sanyou Bio has progressively established a business model driven by AI technology, supported by intelligent R&D platforms, and guided by its innovative drug pipeline. This financing will further accelerate the development and refinement of this integrated system, supporting the company’s evolution from providing innovative drug R&D services toward building pipeline-driven, platform-based, and systematic capabilities for drug innovation and translation.

AI-STAL features a proprietary 11-trillion-scale molecular library, providing a powerful foundation for the discovery of novel molecules at the source of innovative drug development.

SAI-DA integrates dozens of AI algorithms with wet-lab capabilities covering the entire preclinical R&D process, creating an integrated wet-lab and dry-lab drug development accelerator characterized by automation and intelligence.

Clicklinks serves as an open innovation hub for original drug discovery, bringing together global innovation resources and industry partners to foster a collaborative ecosystem for innovative drug R&D.

Together, the three platforms form an integrated, end-to-end system spanning early-stage molecular discovery, R&D acceleration, and the translation of innovative discoveries into tangible outcomes.

From Platform Development to Pipeline-Driven Growth: Turning Innovative Achievements into Industrial Value

Building on its platform capabilities, Sanyou Bio will further focus on pipeline-driven drug development and translation, accelerating the transformation of technological advantages into innovative achievements and industrial value.

To date, the company has established partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide and completed more than 100 collaborative R&D projects, with over 10 innovative drug projects having entered clinical research. In addition, the company has completed 1,000+ drug discovery and stage-specific R&D projects, as well as deliveries of thousands of branded products.

Looking ahead, Sanyou Bio will leverage its three core platforms, global partnership network, and accumulated R&D expertise to further strengthen its independent innovation capabilities and pipeline portfolio. Through platform synergy, project-driven development, and open collaboration, the company aims to improve overall efficiency throughout the drug development process, from early-stage research to downstream translation, and enable more innovative discoveries to realize their industrial value.

Dr. Guojun Lang, Founder and CEO of Sanyou Bio, commented:  “Innovative drug development is a systematic undertaking that requires long-term investment, technological accumulation, and industrial collaboration. Sanyou Bio has always remained committed to its mission of ‘To make it easy to develop new drugs worldwide.’ Through technological innovation and the development of systematic capabilities, we aim to help the industry improve the efficiency of innovative drug R&D, lower barriers to innovation, and empower more partners in drug development.”

“This financing represents recognition of our technological achievements and strategic direction to date, while also providing important momentum as we move into our next stage of development. Going forward, we will continue to invest in the development of our three core platforms—AI-STAL, SAI-DA, and Clicklinks—leveraging AI to empower innovative drug R&D, enhancing R&D efficiency through platform synergy, and further focusing on pipeline-driven drug translation. Our goal is to transform our technological strengths into innovative outcomes with genuine clinical and industrial value.”

“We look forward to working hand in hand with partners around the world to accelerate innovative drug development and bring greater benefits to patients worldwide.”

Ms. Min Yang, Managing Partner of Zero2IPO Group and Managing Partner of Zero2IPO Industry Investment, commented: “Innovative drug development is a field characterized by high technological barriers, deep professional expertise, and long-term value creation. As artificial intelligence and life sciences continue to converge, the industry is facing increasingly demanding requirements for efficient, intelligent, and systematic drug development capabilities.”

“Sanyou Bio has established a systematic strategic framework encompassing early-stage molecular discovery, R&D acceleration, and the development of an open innovation ecosystem. The company has built a solid foundation in technology platforms, collaborative R&D, and industrial resource integration. We are confident in its long-term potential to leverage AI technology to improve drug development efficiency, expand the boundaries of innovation through platform synergy, and unlock industrial value through the translation of innovative drug pipelines.”

“Through this investment, we look forward to supporting Sanyou Bio in further deepening its technological innovation and business development, and working together with the company to promote high-quality growth across the innovative drug R&D industry.”

About Sanyou Bio

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of “To make it easy to develop new drugs worldwide”. Guided by the vision “To become a front-runner in global innovative drug R&D”, the company focuses on the R&D and commercialization of innovative drugs.

With AI-STAL, our world-leading AI-Super-Trillion Antibody Library, as our source of innovation and SAI-DA, our intelligent Sanyou AI-Drug Accelerator integrating dry-lab (in silico) and wet-lab work, as our core engine, we are building Clicklinks, an open innovation system. Driven by new drug pipelines, we accelerate the translation of innovation to benefit broad patient populations.

Headquartered in Shanghai, China, with business centers established across Asia, North America, Europe, and other regions, forming a global business network, Sanyou has more than 20,000 m² of operational and planned R&D and GMP facilities.

Sanyou has established strong partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide. We have signed 100+ collaborative R&D agreements. More than 10 drug candidates from these collaborations have progressed to preclinical or clinical development. We have also completed 1,000+ drug discovery and stage-specific R&D projects and delivered thousands of branded products.

The company has filed more than 180 invention patent applications, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

About Zero2IPO Industry Investment

Zero2IPO Industry Investment is a core business platform under Zero2IPO Group dedicated to industrial investment.

Since its establishment in 2012, the platform has grown to manage nearly RMB 20 billion in assets. Leveraging more than two decades of venture capital ecosystem experience accumulated by Zero2IPO Group, Zero2IPO Industry Investment remains firmly rooted in industrial development. It closely aligns its investment strategies with the diverse development needs of listed companies, family-owned enterprises, and local governments, providing customized industrial investment funds tailored to their specific requirements and connecting resources, industries, and capital across the entire value chain.

The platform currently focuses on key sectors including hard technology, new energy, healthcare, and frontier technologies.

To date, it has invested in and supported dozens of listed companies, including Guoke Tiancheng, Injoinic, MicuRx Pharmaceuticals, Henlius, OneRobotics, Hanchorbio, Zhidian, 160 Health, Tongcheng Travel, and Suntech, as well as more than 100 high-quality growth companies and benchmark projects, including UNISOC, Pins Medical, Baibu, WehandBio, and Volant Aerotech.

SOURCE Sanyou Bio

Recognition marks the third consecutive year CapitalSpring has been named among Inc.’s Founder-Friendly Investors.

NASHVILLE, Tenn., Nov. 9, 2026 — CapitalSpring, a leading private equity and debt investment firm focused on franchised and multi-location businesses, has been named to Inc.’s 2026 Founder-Friendly Investors list, marking the third consecutive year the firm has received the recognition. The annual list recognizes private equity firms, venture capital firms and lenders with a demonstrated commitment to supporting founder-led businesses and helping them accelerate growth.

The recognition reflects CapitalSpring’s approach to partnering with entrepreneurs and management teams through flexible capital solutions, industry expertise and strategic resources. The firm has completed more than 100 investments and has invested $4.6 billion in the sector, with a focus on foodservice, franchised and independent restaurant businesses, multi-location consumer businesses and related industries.

“Being recognized by Inc. for a third consecutive year is meaningful because it reinforces what we believe makes a strong investment partnership: alignment, trust and a shared commitment to building for the long term,” said Erik Herrmann, Partner and Head of the Investment Group at CapitalSpring. “Our goal is never simply to provide capital. We work alongside founders and management teams to understand where they want to take their businesses and bring the resources, experience and flexibility to help them get there.”

CapitalSpring will also connect with restaurant operators, investors and industry leaders at the Restaurant Finance & Development Conference (RFDC), taking place Nov. 9–11 in Las Vegas. The CapitalSpring team will be exhibiting at Booth 601 during the conference, with representatives available Monday, Nov. 9 from 4–7 p.m. and Tuesday, Nov. 10 from 2:30–6 p.m.

To learn more about CapitalSpring, visit CapitalSpring.com.

ABOUT CAPITALSPRING

CapitalSpring is a specialist private equity and debt investment firm with a 20-year track record of investing in franchises and other multi-location businesses that serve the everyday needs of consumers.  The firm has invested over $4 billion across more than 100 investments in 100+ different brands. CapitalSpring has developed competitive advantages including deep sector expertise, proprietary data/benchmarking analytics, an in-house strategic operations team, and a 20-year foundation of relationships driving consistent flow of non-competitive investment ideas and opportunities. CapitalSpring manages multiple fund vehicles including private debt and private equity strategies focused on the lower middle market and middle market. The firm is headquartered in Nashville and has regional offices in Los Angeles, New York and Atlanta. For more information about CapitalSpring, please visit www.capitalspring.com.

MEDIA CONTACT:
Julie Maw
Mainland
209.617.6518
jmaw@hellomainland.com

SOURCE CapitalSpring

Company hits $50M in revenue as agentic AI publishing platform proves a simple principle: AI should empower authors, not replace them

TEL AVIV, Israel and NEW YORK, Nov. 9, 2026 — Spines, the agentic AI publishing platform built to help authors turn written manuscripts into professionally published books, today announced that it has secured $64 million in growth capital to accelerate its expansion, combining a $29 million Series A-1 equity round led by Zeev Ventures, with participation from Aleph, NordStar, M-Fund, LionTree and angel investor Dan Senor, with a $35 million non-dilutive growth financing facility from Twelve.

Spines is also announcing that it has hit $50M in revenue run rate, seeing rapid 400% year-over-year growth as more than 8,000 American authors have published books using the platform, and around 400 new authors join every month.

“We don’t believe the future of publishing is AI writing books. We believe the future is AI giving authors superpowers,” said Yehuda Niv, founder and CEO of Spines. “The writing, the story and the knowledge come from the author. Our job is to build the technology and infrastructure around them; to help more people discover the author within themselves, turn their work into a professionally published book, and ultimately find and reach its audience.”

Authors come to Spines with their own manuscript and use the platform to manage the entire publishing journey. Specialized AI agents perform publishing tasks like editing, proofreading, cover design, formatting, metadata, translation, audiobooks, distribution, royalty management and marketing. Authors can also work with Spines’ in-house human editors, proofreaders, designers and native-speaking language professionals to add additional human expertise and support.

Spines distributes books through 100+ global distribution channels, tracking sales across different platforms and providing a centralized royalty management system that gives authors visibility into what their books are earning across channels and markets. The platform accelerates a process that traditionally took 12-18 months into a matter of weeks, while giving authors greater visibility, flexibility and control throughout their publishing journey.

• Spines now includes tools for audience development and marketing: its campaign management tools help authors create, launch and manage marketing campaigns designed to reach relevant readers, helping authors build demand for their titles.
• Spines is also rapidly expanding its AI-powered translation capabilities. The platform currently supports translation from English into seven target languages: Spanish, Italian, French, German, Portuguese, Polish and Hebrew, combining AI-powered translation with native-speaking human review. Over the next six months, Spines plans to expand that offering to a total of 20 target languages.
• Authors can create professionally narrated audiobooks with Spines using synthetic voices, or create a model of their own voice from a short recording and use it to narrate their book, even in other languages.
• For children’s book authors, Spines has also developed specialized AI illustration technology designed to maintain consistent characters across an entire book, allowing authors to create coherent, professionally illustrated children’s books within the same publishing workflow.

The round was led by Oren Zeev of Zeev Ventures, an early investor in Audible and a longtime investor in category-defining technology companies.

“Spines has all the ingredients to become the category leader in the next generation of publishing,” said Oren Zeev, Founding Partner of Zeev Ventures. “I’ve seen it first-hand; a close friend of mine published his book with Spines and had a great experience. I believe Spines can become the go-to platform for authors around the world to publish their books and reach readers.”

Aleph led Spines’ Seed round and went on to participate in both the Series A and the current Series A-1. Aleph Co-Founder and General Partner Michael Eisenberg, himself  the author of nine books, said:

“Spines’ growth since our seed investment has been extraordinary, and it’s clear that authors are hungry for this kind of AI-powered publishing solution. As an author myself, I know that writing the manuscript is only the first step in bringing a book into the world. Everything that comes afterward can be slow, fragmented and frustrating. What attracted me to Spines from the beginning was the opportunity to use technology to remove that friction without removing the author from the process. AI should amplify human creativity, not substitute for it, and Spines is building the infrastructure to make that possible at global scale.”

“For most of publishing history, gatekeepers decided who was worthy of becoming an author and which stories deserved to reach the world,” Yehuda Niv said. “Anyone with a story, an idea or knowledge to share deserves the opportunity to publish it. Our role is to give creators the tools, infrastructure and reach to find the audience for their work. To me, that’s the real promise of AI in publishing: not replacing writers, but removing barriers so that anyone with a talent for writing can become an author.”

About Spines

Spines is an agentic AI publishing platform built to help authors turn original manuscripts into professionally published books and reach readers around the world. Its publishing operating system combines specialized AI agents with access to human publishing professionals across editing, proofreading, design, formatting, translation, audiobook production, distribution, marketing and royalty management.

Spines works with thousands of authors and distributes titles across more than 100 channels worldwide.

Media Contact
spines@concrete.media

SOURCE Spines

The invitation-only gathering brings together influential voices shaping the future of financial services.

NEW YORK, Nov. 9, 2026 — Byzfunder, a leading technology-driven provider of small business financing, today announced its participation in the 2026 KBW Fintech Ecosystem Conference, taking place November 10–12 at Convene 30 Hudson Yards in New York City.

The conference will feature executives from Visa, Mastercard, American Express, PayPal and Capital One, alongside participants from across the financial technology and investment communities.

Byzfunder’s participation underscores the company’s expanding presence within the financial technology industry and its continued investment in artificial intelligence, proprietary underwriting technology, risk analytics, and scalable financing infrastructure.

Led by CEO Ilya Fridman, Byzfunder has developed an integrated technology platform designed to transform small business financing through intelligent automation, advanced credit decisioning, and data-driven risk management.

“The financial services industry is undergoing a fundamental transformation, driven by artificial intelligence, automation, and increasingly sophisticated data analytics,” said Ilya Fridman, Chief Executive Officer of Byzfunder. “The KBW Fintech Ecosystem Conference brings together an exceptional group of industry leaders and institutional investors who are helping shape that transformation. We look forward to exchanging ideas and exploring opportunities as we continue building the next generation of technology-driven small business financing.”

Byzfunder’s ongoing investment in financial technology and institutional-grade risk management reflects its long-term strategy of combining innovation with disciplined, scalable growth.

About Byzfunder

Byzfunder is a leading financial technology company providing innovative working capital solutions to small and medium-sized businesses nationwide. Combining approximately two decades of industry experience with proprietary technology, artificial intelligence, advanced risk analytics, and automated underwriting capabilities, Byzfunder has developed a scalable financing platform designed to deliver efficient access to capital.

For more information, visit byzfunder.com.

Media Contact

Xin Hamilton, CMO

[email protected]

byzfunder.com

SOURCE Byzfunder

Humans and agents work together to discover, build, and take product to market

LISBON, Portugal, Nov. 9, 2026 — Samepage.ai today launched Samepage Bets, an operating system for product teams in the AI era. One of 15 Web Summit 2026 breakout startups, Samepage will show Bets publicly for the first time on Centre Stage on Wednesday, Nov. 11, before more than 70,000 attendees.

AI has made software faster and cheaper to build, raising the stakes on one question: what should we build next? The answer is scattered across sales calls, CRM records, support tickets, competitor launches, and internal chat.

Bets brings that work onto one board. An Insights Inbox automatically triages feature requests, bugs, competitor moves, and evidence from more than 50 native integrations across CRM, call recordings, support, the web, and internal communication. Each insight can become a bet that moves through three stages:

• Planning: Research and requirements agents build the case, backed by customer evidence and a priority score.
• Building: Prototyping and coding agents work in the team’s codebase and open pull requests in GitHub.
• Go-to-market: A product marketing agent publishes release notes to Notion and support articles to Intercom.

Humans stay in the loop: AI agents take the first pass, and a person reviews the work before it moves on. Bets is fully interoperable, reading from and writing to Jira, Linear, GitHub, Slack, Notion, and more, so status and comments stay in sync everywhere.

Bets is also multiplayer: engineering, product marketing, and other partners stay on the same page from one board.

“AI made building fast. Now the hard part is making sure you’re building the right thing,” said Sahil Jain, co-founder and CEO of Samepage. “Bets gives product teams one place where agents do the heavy lifting and humans make the calls, from the first customer signal all the way to launch.”

Bets builds on Samepage Signals, launched in June alongside $4.85 million in seed funding. Signals surfaced the insights; Bets turns them into a launched product.

“I built something like this for myself in Claude. Samepage Bets thought of things I hadn’t, and gives our team a consistent flow,” said Ben Silver, head of product at MCL Finance.

“We could have pieced something together in Claude, but we’d have ended up maintaining a tool instead of building our product,” said Nick Reid, head of product and AI operations at Customer Alliance.

Samepage Bets is available today, and teams can get started for free at samepage.ai.

About Samepage

Samepage is the operating system for product teams in the AI era. Its flagship product, Samepage Bets, brings humans and agents together to discover, build, and launch product across more than 50 native integrations. Founded by the team behind AdStage, Samepage is backed by Craft Ventures, Freestyle VC, and Glasswing Ventures. Learn more at samepage.ai.

Media contact: Sahil Jain, CEO & Co-founder, Samepage.ai, press@samepage.ai, +1 (415) 409-8440

SOURCE Samepage, Inc.

AMSTERDAM, Nov. 9, 2026 — Onodrim Industries (“Onodrim”), the European defence and industrial scale-up platform, today announced a $300 million Series A led by Lux Capital, with participation from new and existing investors including General Catalyst, Lakestar, Altimeter, Strike Capital, 137 Ventures, 8090, Expeditions, and more. The financing values Onodrim at $1.3 billion and follows the $45 million seed round announced earlier this year.

Onodrim will use the capital to acquire established businesses across aerospace and defence, and industrial manufacturing. The company takes controlling stakes with permanent capital and applies cutting-edge technology, operational and business development expertise to accelerate their growth. Onodrim focuses on dual-use businesses in critical industries across supply chains, services, and products that solve major bottlenecks for the European defence industry. Onodrim and its companies are united by a common mission: strengthening Europe’s defence and industrial foundations.

“Europe has no shortage of exceptional companies. The challenge has been access to the resources needed to help them grow at the scale and speed the moment demands,” said Aistis Šimaitis, Co-Founder and CEO of Onodrim. “We are bringing permanent capital, technology and world-class operators to Europe’s best companies, giving them the resources to expand, compete and strengthen the continent’s defence industrial base.”

“Europe needs a stronger industrial foundation to meet the security challenges ahead,” said Brandon Reeves, Partner at Lux Capital. “We see an enormous opportunity to bring a new model of ownership and investment to the continent’s most important businesses. Aistis and Alex have assembled an exceptional team with the technical depth and operational experience to realize that opportunity, combining permanent capital with the ambition to build businesses for the long term.”

Onodrim expects to announce its first acquisitions in the coming months. The company is also expanding its European presence with the office openings of Onodrim Germany in Munich and Onodrim Italy in Turin, joining its existing offices in Amsterdam, London and Vilnius.

“Every country needs to be in control of its own destiny, and that starts with what it can build,” said Jeannette zu Fürstenberg, President and Managing Director at General Catalyst. “Europe’s established manufacturers already have the expertise, customers, and trust. What they need is technology that helps them evolve and take on larger programmes. Aistis and Alex have reimagined what an industrial group can be, matching world-class engineering talent with deep respect for the businesses they join. That is how Europe’s industrial base renews itself from within.”

Onodrim is led by Co-Founder and CEO Aistis Šimaitis, a former advisor to the Lithuanian Government and technology leader at Palantir Technologies, who holds a DPhil from the University of Oxford, and Co-Founder and CTO Alexander Blessing, formerly Forward Deployed Engineer at Palantir Technologies, who holds degrees from Stanford University and the University of Cambridge. Christian Garrett, Partner at 137 Ventures, is also a co-founder.

The company has assembled a global and diverse team spanning private equity, aerospace and defence, technology, and government. Its shared purpose is to rebuild Europe’s industrial capacity and strengthen its security.

Companies backed by Onodrim gain capital, operational, business development, and technology resources to grow faster, take on larger programmes and serve customers across Europe. They also gain access to engineering teams that can develop new products and modernize manufacturing and operations, backed by a platform built to scale alongside them.

“Our approach at Onodrim is rooted in long-term partnership and collaboration. We believe Europe’s industrial champions are built by investing in great businesses, empowering the people behind them and giving them the resources to grow for the long term,” said Alex Blessing. “We welcome approaches from owners of defence, aerospace, manufacturing and industrial businesses who share this ambition, as well as exceptional engineering and operational talent looking to help build Europe’s industrial future.”

About Onodrim Industries

Onodrim Industries is a European, technology-driven scale-up platform that strengthens the continent’s defence and industrial foundations. It brings technology, capital and operational expertise to critical industries, including defence, aerospace, and manufacturing. Its leadership draws on senior experience in private equity, government, advanced engineering and global technology companies.

SOURCE Onodrim Industries B.V.

HANGZHOU, China, Nov. 6, 2026 — Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) (“Zylox-Tonbridge”) today announced a strategic investment in LifeTech Scientific Corporation (HKEX: 1302) (“LifeTech”), in partnership with GL Capital, marking a significant step toward building a leading integrated vascular and structural heart intervention platform in China.

The investment is expected to bring together Zylox-Tonbridge’s peripheral vascular and neurovascular businesses with LifeTech’s aortic and structural heart businesses, creating a comprehensive portfolio across four key therapeutic areas. The companies also aim to leverage their complementary R&D capabilities and global commercial networks to accelerate innovation and expand their international reach.

Under the agreement, Zylox-Tonbridge and GL Capital will jointly invest approximately HK$1.482 billion in LifeTech through GL Lighthouse Two Investment Limited (“Lighthouse Two”), which will subscribe for newly issued shares representing approximately 16.7% of LifeTech’s enlarged share capital. Upon completion, Lighthouse Two will become LifeTech’s largest single shareholder, with Zylox-Tonbridge holding a 60% stake in Lighthouse Two through an investment of approximately HK$889 million.

In a related transaction, GL Capital will subscribe for 39.8 million newly issued Zylox-Tonbridge shares at HK$22 per share, representing approximately 10.8% of the company’s enlarged issued share capital. The subscription price represents a 13.5% premium to the closing share price on the announcement date and a 15.4% premium to the average closing price over the preceding five trading days, reflecting GL Capital’s confidence in Zylox-Tonbridge’s long-term prospects. The proceeds will support Zylox-Tonbridge’s potential future investments in LifeTech and international business development.

Beyond the investment, Zylox-Tonbridge and GL Capital may acquire additional shares in LifeTech to support closer collaboration and business growth. Zylox-Tonbridge also intends to pursue a potential merger with LifeTech, with the aim of building a leading integrated vascular and structural heart intervention platform in China.

Bringing Together Complementary Strengths Across Four Therapeutic Areas

LifeTech is a leading medical device company in China specializing in cardio-cerebrovascular and peripheral vascular interventions, with an established position in aortic and structural heart interventions. The company has developed a comprehensive portfolio of endovascular solutions for complex aortic diseases, including aortic arch and branch vessel reconstruction. Its structural heart portfolio includes the LAmbre™ and LAxible™ left atrial appendage occluders and three generations of congenital heart defect occluders.

LifeTech has also developed several first-in-class products, including the G-Branch™ thoracoabdominal aortic stent graft system, Concave Supra-arch branched stent-graft system and SureCham™ aortic arch single branch stent graft system. The company holds more than 50 medical device registration certificates in China, with 20 products accepted into China’s special review procedure for innovative medical devices. As of June 30, 2026, LifeTech had filed 2,608 valid patent applications, including 1,370 valid granted patents.

Zylox-Tonbridge brings complementary expertise in peripheral vascular and neurovascular interventions through its two brands, Zylox Medical and Tonbridge Medical. The company is one of the few in China offering comprehensive product solutions across both areas, with strong R&D, manufacturing and commercialization capabilities. Since the beginning of 2025, six additional Zylox-Tonbridge products have been accepted into China’s special review procedure for innovative medical devices. The company now serves more than 3,500 hospitals across China.

The strategic investment is expected to help both companies expand their businesses and strengthen their market positions.

Strengthening the Global Competitiveness of Chinese MedTech Brands

The companies’ established international commercial networks offer further opportunities for collaboration and market expansion.

Zylox-Tonbridge reported a 349.3% year-over-year increase in revenue from markets outside Mainland China in the first half of 2026. The company has commercialized its products in over 70 countries and regions outside Mainland China, supported by a distribution network covering more than 135 countries and regions.

Zylox-Tonbridge has strengthened its local operations in Europe through the acquisition and integration of Germany-based vascular intervention company optimed. The company continues to expand its presence across key markets in Europe, Latin America and Asia.

LifeTech also has an established international presence, with seven subsidiaries outside Mainland China and a sales network spanning nearly 120 countries and regions. In 2025, its revenue from markets outside Mainland China reached nearly RMB400 million, up approximately 14.4% year over year and accounting for nearly 30% of total revenue. Europe and Asia were its primary international revenue contributors.

The strategic investment is expected to create opportunities for the companies to leverage their complementary product portfolios, commercial networks and operating capabilities, strengthening the competitiveness of Chinese MedTech brands in international markets.

Leadership Perspectives

Dr. Jonathon Zhong Zhao, Chairman of Zylox-Tonbridge, said:

“This strategic investment marks an important milestone in our ambition to build a leading integrated vascular and structural heart intervention platform in China. By combining our strengths in peripheral and neurovascular interventions with LifeTech’s expertise in aortic and structural heart interventions, we aim to establish a more comprehensive portfolio and create new opportunities for long-term growth.

“With our established operating capabilities and expanding global presence, we see significant opportunities to capture synergies, strengthen our competitiveness and advance our growth as a global medical technology company.”

Mr. Zhenfu Li, Founder, Managing Partner and Chief Executive Officer of GL Capital, said:

“GL Capital has long been committed to supporting leading healthcare companies in China through long-term investment and strategic support. We see significant potential in China’s vascular intervention market and the global growth prospects of innovative Chinese medical technology companies.

“This strategic investment provides an opportunity to bring together complementary resources and advance our shared goal of building a globally competitive vascular and structural heart intervention platform. We will continue to leverage our capital and industry resources to strengthen the companies’ competitiveness and support their global expansion.”

Mr. Yuehui Xie, Founder of LifeTech Scientific, said:

“This strategic investment reflects strong confidence in LifeTech’s innovation capabilities, market position and long-term growth potential. Zylox-Tonbridge and LifeTech have highly complementary businesses, product portfolios and commercial networks, creating opportunities for closer collaboration and greater synergies.

“The investment marks a new chapter for LifeTech, with the potential to strengthen our competitive position through closer collaboration in products, technologies and resources. As Senior Advisor, I will continue to contribute my nearly three decades of industry experience to LifeTech’s long-term development, with a deep personal commitment to the company’s continued growth and success.”

About Zylox-Tonbridge

Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) is a leading vascular intervention medical technology company in China, focused on the research, development, manufacturing and global commercialization of innovative medical devices. Its brands include Zylox Medical and Tonbridge Medical, which specialize in peripheral vascular and neurovascular interventions, respectively.

Zylox-Tonbridge has established a comprehensive portfolio of innovative products, with 69 products approved by China’s National Medical Products Administration (NMPA) as of August 2026. Its products are commercialized in 70 countries and regions outside Mainland China. Listed on the HKEX in 2021, the company is pursuing its strategy to build a globally competitive vascular and structural heart intervention platform.

About GL Capital

GL Capital is a China-focused healthcare investment firm founded in 2010 by Jeffery Li, former President of Novartis China. The firm specializes in healthcare buyout and growth investments and manages more than RMB30 billion in assets across U.S. dollar- and RMB-denominated private equity, venture capital and hedge funds.

GL Capital focuses on investments in healthcare companies with sustainable competitive advantages and works with management teams to support long-term business development and value creation.

About LifeTech Scientific

Established in 1999 in Shenzhen, China, LifeTech Scientific Corporation (HKEX: 1302) specializes in the research, development, manufacturing and commercialization of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases.

The company has established a comprehensive product portfolio in aortic and structural heart interventions and developed the world’s first iron-based bioabsorbable material technology platform. LifeTech maintains leading market positions in China for its key products and was among the first Chinese medical device companies to achieve large-scale international commercialization of high-value medical devices. Its global sales network spans nearly 120 countries and regions, supported by more than 1,000 distributors.

SOURCE ZYLOX-TONBRIDGE